[T-activin in the combined treatment of patients with small cell cancer of the lung].
T-activin immunotherapy in conjunction with maintenance chemotherapy was given to 13 patients suffering small-cell carcinoma of the lung in whom previous cytostatic and combined treatment (chemotherapy+radiation) resulted in a complete regression of tumor. The median survival time in those patients was 113 weeks versus 75 weeks in 13 controls. The results make the case for further studies on application of the said agent aimed at longer survival and remission in patients with small-cell carcinoma of the lung.
Ausekar
B V
BV
Perevodchikova
N I
NI
Kadagidze
Z G
ZG
Derevnina
N A
NA
Veskova
T K
TK
D000206:Actuarial Analysis; D000917:Antibody Formation; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018288:Carcinoma, Small Cell / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D007958:Leukocyte Count; D008175:Lung Neoplasms / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D008727:Methotrexate / Q000008:administration & dosage; D010455:Peptides / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000276:immunology; D013949:Thymus Extracts / Q000627:therapeutic use*
D010455:Peptides; D013949:Thymus Extracts; D004317:Doxorubicin; C036191:T-activin; D003520:Cyclophosphamide; D008727:Methotrexate
T-aktivin v kompleksnom lechenii bol'nykh melkokletochnym rakom legkogo.